To address this challenge, we designed dual-functional liposomes, by adding a second ligand, anti-CA IX antibody, selective for CA IX receptors, known to be over-expressed in the cell-surfaces of most in vivo tumor sites. This evidence concerns the gene CA9 and neoplasm.